Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy

Figure 1

PSA levels in logarithm scale for each patient. Blue line (N = 6) represents the slope of PSA during isoflavone therapy was significantly lower than that before the therapy, red line (N = 2) represents the slope of PSA during isoflavone therapy was significantly higher than that before the therapy and black line (N = 12) represents the slope of PSA during isoflavone therapy was unchanged than that before the therapy. CAG, CAG androgen receptor polymorphisms. D, subject who dropped out before completion of the therapy.

Back to article page
\